Loading...

VVOS VIVOS THERAPEUTICS INC Capital Structure Changes 8-K Filing

VVS

VVS

VIVOS THERAPEUTICS INC

(VVOS)

2025 8-K

Show Summary

Summary

Asset Acquisitions

Asset Acquisitions

Financial Statements

Asset Purchase Agreement

Financial Results

Securities Offering

Annual Meeting Results

Q3 Financial Results

Annual Meeting Notice

Equity Incentive Plan

Q2 Financial Results

Non-Compliance with Nasdaq ...

Compliance with Stockholder...

Private Placement and Strat...

Delisting Notice

Financial Results Announcement

Compliance with Minimum Sto...

Financial Results Announcement

Entry Into a Material Defin...

Non-compliance notice from ...

Private Placement

Reverse Stock Split

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Delisting Notice

Change in Accounting Firm

Financial Results Announcement

Acquisition of Intellectual...

Private Placement

External Links:

Vivos Therapeutics, Inc. has entered into an agreement to sell up to $3,328,881 worth of its common stock through H.C. Wainwright & Co., LLC, and has also amended employment agreements for its CEO and CFO effective January 1, 2025.

AI Assistant

VIVOS THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.